Altimmune’s (ALT) Market Perform Rating Reiterated at William Blair

William Blair reissued their market perform rating on shares of Altimmune (NASDAQ:ALT) in a research note issued to investors on Friday,RTT News reports.

Several other research analysts have also recently weighed in on the stock. Stifel Nicolaus started coverage on shares of Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Altimmune in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Stock Up 13.8 %

Altimmune stock opened at $5.92 on Friday. The stock has a market cap of $455.92 million, a P/E ratio of -3.82 and a beta of 0.87. Altimmune has a twelve month low of $5.14 and a twelve month high of $11.16. The company’s 50-day moving average price is $6.48 and its two-hundred day moving average price is $7.12.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. Equities analysts anticipate that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $52,000. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 4.10% of the stock is currently owned by company insiders.

Institutional Trading of Altimmune

Several large investors have recently made changes to their positions in the company. Larson Financial Group LLC acquired a new stake in Altimmune in the third quarter valued at approximately $31,000. SBI Securities Co. Ltd. acquired a new stake in Altimmune in the fourth quarter valued at approximately $45,000. Virtus ETF Advisers LLC acquired a new stake in Altimmune in the fourth quarter valued at approximately $60,000. Cullen Frost Bankers Inc. acquired a new stake in Altimmune in the fourth quarter valued at approximately $72,000. Finally, Sunbelt Securities Inc. boosted its position in Altimmune by 356.8% in the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock valued at $79,000 after buying an additional 8,470 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.